Member Info for flyingmachine

Yakya, I am sure the AIHL prospectus and numbers will be laid out again at next weeks presentation so I encourage you to attend and listen in to make up your own mind.

No doubt there will be coverage of the AIHL test in next weeks presentation. I would expect to hear that formal launch and marketing push of the product will commence as soon as the Liverpool and Manchester trial is complete. I understand these trials have progressed steadily despite the pandemic since babies are still born everyday and some end up in ICU, so I am expecting the trials to be completing soon.

With or without Covid tests, I will repeat, with or without Covid tests, AIHL will become a consistent annual earner for Genedrive, up £60m annually (nearly double today's Mcap ) - it is unique and will become a 'must have' test for babies entering ICU in the UK, Europe and the USA.

There is no doubt that the UK and other countries will need as many LFT tests as any manufacturer can produce, whether that's test 1, test 2 , test 3, test 4 etc etc. Any manufacturer will benefit from this explosive need for faster LFT tests.

Omega position has therefore not changed significantly in my mind whether or not they will produce more or less UK-RTC antibody tests. They will still make as many tests as they have manufacturing capacity for.

So this 'noise' we heard today that caused the SP drop, is just 'noise' and I believe bears little relation to the outcome that ODX will still end up manufacturing 1m LFT tests per week within the next few months.

I would invest in Genedrive - unique first-to-market AIHL test, already CE marked. Currently being used in Liverpool and Manchester trial and formal launch/marketing will occur after that is complete. However, commercial distribution already started and being sold. Remembewr this test will be almost become mandatory in countries like the USA, to avoid ICU babies losing their hearing and hospitals facing law suits from angry parents.

Expected Market is at least 90k tests/year in just the UK, the USA and Europe market are each 5 times bigger. Genedrive anticipate earnings from this test to amount to £40-£65m per year. So earnings per year for Genedrive from the AIHL test could be nearly twice today's Mcap. Just on AIHL test alone the Mcap can go many multiples of where the SP is now. This is without any impact from future HCV and USA DoD test sales, and no reliance on Covid sales.

So Genedrive is not primarily a Covid play.

I imagine alot of folks have lost focus on the AIHL test from Genedrive.

Still in hospital trials in Liverpool and Manchester, with positive results previously reported by Genedrive, but until trials are complete, no formal launch as yet. Although not formally launched, I understand it is on sale and commercial roll-out has begun.

Genedrive projected a UK market of 90k AIHL tests per year in just the UK @ £35 per test. The market in USA and rest of Europe are each 5 times the size of UK market. Genedrive expect to make up to £60m/year from these tests (when formally launched). That is nearly double the current Mcap of Genedrive. So much more poential from where we are today, even without the Covid tests.

FinnCap - "Don’t jump the gun, the #Pfizervaccine is great news but many questions & challenges remain. While a major addition to our armoury in the #COVID19 fight, it's no silver bullet & won't replace need for treatments or tests."

Text of FinnCap News alert is here....

https://www.finncap.com/uploads/media/5faa80f7ae654/health-matters-10th-november-2020-covid-19-news-alert.pdf?v1

Some other science feedback on vaccine news here....

https://www.sciencemediacentre.org/expert-reaction-to-pfizer-and-biontech-reporting-interim-results-from-phase-3-covid-19-vaccine-trial/

The need for testing isn't disappearing any time soon....

FinnCap - "Don’t jump the gun, the #Pfizervaccine is great news but many questions & challenges remain. While a major addition to our armoury in the #COVID19 fight, it's no silver bullet & won't replace need for treatments or tests."
Text of FinnCap News alert is here....

https://www.finncap.com/uploads/media/5faa80f7ae654/health-matters-10th-november-2020-covid-19-news-alert.pdf?v1

Some other science feedback on vaccine news here....

https://www.sciencemediacentre.org/expert-reaction-to-pfizer-and-biontech-reporting-interim-results-from-phase-3-covid-19-vaccine-trial/

The need for testing isn't disappearing any time soon....

FinnCap - "Don’t jump the gun, the #Pfizervaccine is great news but many questions & challenges remain. While a major addition to our armoury in the #COVID19 fight, it's no silver bullet & won't replace need for treatments or tests."

The above was also referenced by Genedrive tweet.

Text of FinnCap News alert is here....

https://www.finncap.com/uploads/media/5faa80f7ae654/health-matters-10th-november-2020-covid-19-news-alert.pdf?v1

Some other science feedback on vaccine news here (also taken from Genedrive tweet)....

https://www.sciencemediacentre.org/expert-reaction-to-pfizer-and-biontech-reporting-interim-results-from-phase-3-covid-19-vaccine-trial/

The need for testing isn't disappearing any time soon....

If Biden wants to increase USA testing significantly (7 fold) then mass automated testing in labs eg BC/Gendrive is going to have a significant impact.

I believe there has been over or knee-jerk reaction in the Market today. I see a Covid testing share across the pond lost 42% at one point today and then finished even!

Expect a recovery.

The vaccine news announced today was good for the ultimate belief that a vaccine against the virus is possible but there are still many challenging milestones for the Pfizer vaccine to reach, so even though a possible vaccine is on the horizon the period of mass roll-out of the 40 million doeses that the Gov have ordered I suggest is still a fair distance away. In the meantime, testing, testing and testing is still required to manage the pandemic in the UK and across the world.

I am expecting many companies in the Covid testing space, including Omega, to give their own perspective on today's vaccine news over the coming days. Certainly, I expect antibody testing to remain significant, even during the period after we get a fully approved vaccine.

The vaccine news announced today was good for the ultimate belief that a vaccine against the virus is possible but there are still many challenging milestones for the Pfizer vaccine to reach, so even though a possible vaccine is on the horizon the period of mass roll-out of the 40 million doeses that the Gov have ordered I suggest is still a fair distance away. In the meantime, testing, testing and testing is still required to manage the pandemic in the UK and across the world.

I am expecting many companies in the Covid testing space, including Avacta, to give their own perspective on today's vaccine news over the coming days.

The vaccine news announced today was good for the ultimate belief that a vaccine against the virus is possible but there are still many challenging milestones for the Pfizer vaccine to reach, so even though a possible vaccine is on the horizon the period of mass roll-out of the 40 million doeses that the Gov have ordered I suggest is still a fair distance away. In the meantime, testing, testing and testing is still required to manage the pandemic in the UK and across the world.

I am expecting many companies in the Covid testing space, including Genedrive, to give their own perspective on today's vaccine news over the coming days.

...and LHGP are still fully supporting DIVOC and Genedrive in India.....

https://www.lhgp.com/news/divoc-labs-secures-nabl-certification-and-icmr-permission-to-offer-c-19-testing

I came across an Indian news article below which indicated even Indian developed tests have been frustrated by long delays in ICMR approval......

https://www.hindustantimes.com/cities/four-months-on-csir-awaits-icmr-approval-for-dry-swab-test/story-5zRuiRddXUwvQy3tY4X7yK.html

I know that enquiries to ICMR asking about any reasons for the delay have been made but with little response from ICMR, so looks like there have been bureaucratic challenges over there.......but it will come.

Thanks Safy. Been invested here since the summer and added a little more post the drop yesterday. I am in 3 Covid plays, all hopefully complementing each other as we 'test' our way out of the lockdowns over the next few months. I have been quiet on the boards recently but keeping an eye on things....

Yes, that answers the capacity question for 500k tests per week up till the end of this year - all taken up by RTC and Mologic. CK are looking for potential further expansionu p to 2.5m per week in early 2021. We will have to wait for further news and clarification about what that will be used for - quite likely more RTC/Mologic tests but could also be 'other' customers. All profit for ODX.

CK stated that they expected MHRA feedback for the RTC antbody test shortly - either approval or more information required. So MHRA news can still arrive at any time. If it's approval then that unleashes the shackles for more and greater orders for the test from the Gov, far beyond the initial 1m order.

In any case, I expect ODX to be able to sell as many CE marked LFD tests as they can make, with or without the Gov's help.

...I should have added....another first post wonder....Lol!!

Dr Michaels, can someone correct you if the placing was not done in March? Lol.......you have no credibility! You are talking about placings and do not even know when the last was executed. I'll give you a clue, it was more recent than March.